



Contact: Tricia J. Richardson  
Novavax, Inc.  
240-268-2031

## **Novavax CEO to Present at The World Vaccine Congress 2009, Lyon, France**

Rockville, MD (October 6, 2009) – /prnewswire-firstcall/ - Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and CEO of Novavax, will be making two presentations at the World Vaccine Congress 2009 conference on October 7<sup>th</sup>, 2009 at the Palais des Congrès de Lyon, Lyon, France. The first presentation by Dr. Singhvi titled, ‘Innovative Approaches to RSV vaccine development and VLP based vaccines’ will be presented under the ‘FUTURE DIRECTION OF VACCINE R&D’ section. The second presentation, ‘How to advance manufacturing using scalable solutions’ will be presented under the “CELL CULTURE BASED PRODUCTION – THE NEXT FRONTIER?” session.

### **ABOUT NOVAVAX**

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at [www.novavax.com](http://www.novavax.com) and in the Company’s various filings with the Securities and Exchange Commission.

###